182683-50-7
182683-50-7 結(jié)構(gòu)式
基本信息
KNTBAGOTDJPUJV-XMTFRXHISA-N
L-α-Glutamyl-L-alanyl-L-valyl-L-seryl-L-leucyl-L-lysyl-L-prolyl-L-threonine
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-P0154 | PKCε Inhibitor Peptide Epsilon-V1-2 | 182683-50-7 | 5mg | 1800元 |
| 2026/06/05 | HY-P0154 | PKCε Inhibitor Peptide Epsilon-V1-2 | 182683-50-7 | 10mg | 3200元 |
| 2024/08/19 | HY-P0154 | PKCε Inhibitor Peptide Epsilon-V1-2 | 182683-50-7 | 25 mg | 6400元 |
常見問題列表
|
PKCε
|
Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide containing the site for its specific receptor for activated C kinase (RACK), inhibits translocation of PKCε and reduces insulin response to glucose.
Epsilon-V1-2 (ε-V1-2; 1 μM, 24 hours) treatment significantly inhibits Oleic acid (OA)-induced connexin 43 (Cx43) Ser368 phosphorylation and prevents OA-induced gap junction disassembly in cardiomyocytes.
Epsilon-V1-2 (20 mg/kg/day; osmotic pumps; daily; for 4 weeks) treatment significantly improves the beating score in a murine heterotopic transplantation model. Epsilon-V1-2 reduces infiltration of macrophages and T cells into the cardiac grafts, and decreases parenchymal fibrosis. Epsilon-V1-2 treatment almost abolishes the rise in pro-fibrotic cytokine, TGF-β and monocyte recruiting chemokine MCP-1 levels.
| Animal Model: | C57BL/6J mice transplanted the hearts of FVB mice |
| Dosage: | 20 mg/kg/day |
| Administration: | 0.1 mL osmotic pumps implanted subcutaneously; daily; for 4 weeks |
| Result: | Significantly improved the beating score throughout the treatment. |